Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:2973
Structure:
Synonyms:
1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetyl hydroxylamino)-6,11,17,22-tetraazaheptaeicosane
138-14-7 (MESYLATE)
1950-39-6 (HCL)
2C10H20N2O3.C5H13N.C3H7NO2
3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone,
3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-
30-Amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone
70-51-9
70-51-9 (FREE BASE)
7278-84-4
AB00053447
AIDS-002640
AIDS002640
Ba 29837
Ba 33112
Ba-29837
Ba-33112
BPBio1_000716
BRN 2514118
BSPBio_000650
BSPBio_002131
Butanediamide, N'-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxy-
Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-
C06940
CGH-749B
CHEBI:4356
cMAP_000047
D03670
DB00746
Deferoxamide B
Deferoxamin
Deferoxamina
Deferoxamina [INN-Spanish]
Deferoxamine
Deferoxamine (USAN)
Deferoxamine B
Deferoxamine Mesylate
Deferoxamine [USAN:INN]
Deferoxaminum
Deferoxaminum [INN-Latin]
Deferrioxamine
Deferrioxamine B
Desferal
Desferal Mesylate
Desferan
Desferex
Desferin
Desferral
Desferriferrioxamin B
Desferrin
Desferrioxamin
DESFERRIOXAMINE
Desferrioxamine B
DF B
DFO
DFOA
DFOM
DFX
DivK1c_000082
EINECS 200-738-5
Ferrioxamine B, N-benzoyl-
HSDB 3311
ICL-749B
IDI1_000082
KBio1_000082
KBio2_001372
KBio2_002429
KBio2_003940
KBio2_004997
KBio2_006508
KBio2_007565
KBio3_001351
KBio3_002908
KBioGR_000922
KBioGR_002429
KBioSS_001372
KBioSS_002435
LS-124964
N'-(5-((4-((5-(Acetylhydroxamino)pentyl)amino)-1,4-dioxobutyl) hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxybutanediamide
N'-[5-(acetyl-hydroxy-amino)pentyl]-N-[5-[3-(5-aminopentyl-hydroxy-carbamoyl)propanoylamino]pentyl]-N-hydroxy-butane diamide
N'-[5-(acetyl-hydroxyamino)pentyl]-N-[5-[[4-(5-aminopentyl-hydroxyamino)-4-oxobutanoyl]amino]pentyl]-N-hydroxybutanediamide
N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide
N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide
N-(5-(3-((5-Aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)propionohydroxamic acid
N-(5-{3-((5-Aminopentyl)hydroxycarbamoyl)propionamido}pentyl)-3-{(5-(N-hydroxyacetamido)pentyl)carbamoyl}propionohydroxamic acid
N-Benzoylferrioxamine B
NCGC00178802-01
NCGC00178802-02
nchembio.2007.23-comp8
NCI60_002181
NINDS_000082
NSC-527604
NSC268993 (HCL)
NSC527604
NSC527604 (FREE BASE)
NSC644468 (MESYLATE)
N~1~-(5-(Acetyl(hydroxy)amino)pentyl)-N~4~-(5-((4-((5-aminopentyl)(hydroxy)amino)-4-oxobutanoyl)amino)pentyl)-N~4~-hydroxysuccinamide
Perineurin
Prestwick0_000725
Prestwick1_000725
Prestwick2_000725
Prestwick3_000725
Propionohydroxamic acid, N-(5-(3-((5-aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)-
Propionohydroxamic acid, N-[5-(3-[(5-aminopentyl)hydroxycarbamoyl]propionamido)phentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)-
Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[(5-N-hydroxyacetamido)pentyl]carbamoyl]-
Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-
SMP2_000121
SPBio_001109
SPBio_002589
Spectrum2_001155
Spectrum3_000376
Spectrum4_000311
Spectrum5_000827
Spectrum_000892
WLN: Z5NQV/2VM5NQV/ 21
ATC-Codes:
Side-Effects:
Side-EffectFrequency
loss of vision0.0010
pain0.0010
paraesthesia0.0010
pruritis0.0010
retinal degeneration0.0010
visual field defects0.0010
swelling0.0010
tinnitus0.0010
erythema0.0010
urticaria0.0010
vascular disorders0.0010
vomiting0.0010
encephalopathy0.0010
cataracts0.0010
bone pain0.0010
myalgia0.0010
lung infiltration0.0010
blurred vision0.0010
optic neuritis0.0010
night blindness0.0010
nausea0.0010
diarrhea0.0010
corneal opacities0.0010
connective tissue disorders0.0010
asthma0.0010
arthralgia0.0010
angioneurotic oedema0.0010
anaphylactic shock0.0010
abdominal pain0.0010
dizziness0.0010
oedema0.0010
mediastinal disorders0.0010
hypotension0.0010
blood disorder0.0010
deafness neurosensory0.0010
headache0.0010
gastroenteritis0.0010
pyrexia0.0010
rash0.0010
allergic reaction0
infection0
retinopathy0
neuropathy0
ards0
tachycardia0
dyspnea0
leg cramps0
thrombocytopenia0
hypersensitivity0
dysuria0
leukopenia0

Target

show target details
Uniprot ID:Q8C3V7_MOUSE
Synonyms:
Ferrochelatase
EC-Numbers:4.99.1.1
Organism:Mouse
Mus musculus
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

8018536
A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin.. S Iinuma; S S Farshi; B Ortel; T Hasan (1994) British journal of cancer display abstract
5-Aminolaevulinic acid (ALA)-induced porphyrin biosynthesis and phototoxicity in vitro was investigated in five malignant and two normal cell lines. Intracellular protoporphyrin IX (PpIX) content was quantified by extraction and fluorescence spectroscopy. Cellular PpIX content did not always correlate with cell proliferation rate as measured by the doubling times of cell lines. Cellular efflux of PpIX was also investigated. In a bladder carcinoma cell line, the observed rapid efflux was not blocked by verapamil, an inhibitor of the P-glycoprotein efflux pump. These data support the view that cellular PpIX accumulation is a dynamic process that is determined by both the efflux of PpIX from the cells and enzyme activities in the haem biosynthesis pathway. Desferrioxamine (desferal), a modulator of PpIX biosynthesis, enhanced ALA-induced cellular PpIX content significantly in all carcinoma cell lines but not in non-malignant cell lines. The enhanced PpIX cellular accumulation is attributed to inhibition of ferrochelatase activity, the enzyme responsible for the conversion of PpIX to haem. PpIX-mediated cellular photodestruction following irradiation with an argon ion laser at 514.5 nm was determined by the 'MTT assay'. There appeared to be a 'threshold' effect of cellular PpIX content; cells that synthesised less than 140 ng/mg-1 protein exhibited very little phototoxic damage, while cell lines having greater than 140 ng PpIX/mg-1 protein [corrected] exhibited a consistent phototoxic response. Among the cell lines which did undergo phototoxic damage, there was not a strict correlation between PpIX cellular content and ALA-induced phototoxicity. Desferal enhanced the PpIX content and phototoxic effect in the responsive cells. Fluorescence microscopy of the ALA-treated cells revealed marked accumulation of PpIX in mitochondria (rhodamine 123 co-staining). That the primary site of phototoxic damage is also the mitochondria was confirmed by electron micrographs of cells photosensitised with ALA-induced PpIX, which showed swelling of mitochondria within minutes after irradiation while other suborganelles appeared to be unaffected. The repair or further destruction of the mitochondria was fluence and cell-type dependent. The data from this study suggest that the basis of increased ALA-induced PpIX accumulation in tumours is a combination of various aspects of the metabolic process and pharmacokinetics and that the efficacy of photodestruction of malignancy will be determined not only by the rate of PpIX synthesis but also by specific cellular and tissue characteristics.